Precigen Inc. (PGEN) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. BROS
5. FIS
6. DDOG
7. QCOM
8. EW
9. ZG
10. W

Go back to Precigen Inc. (PGEN) Reports In-Line Q3 EPS

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

November 9, 2023 4:55 PM EST

   Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval request, the Company has expedited efforts to attain commercial readiness

    Full results of the Phase 1 portion of the ongoing Phase 1/2 study of PRGN-2012 were published in the peer-reviewed journal, Science Translational Medicine, and presented in an oral presentation at the ESGCT 30th Annual Congress

   Enrollment and dosing was completed in the Phase 2 study of PRGN-2012 in RRP; Phase 2 study... More